Effect of Rowachol on Prevention of Postcholecystectomy Syndrome
Effect of Rowachol on Prevention of Postcholecystectomy Syndrome
Postcholecystectomy syndrome (PCS) includes a heterogeneous group of diseases, usually
 manifested by the presence of abdominal symptoms following gallbladder removal. The
 pathogenesis of PCS has not been identified; therefore there is no consensus of medical
 treatment on PCS. The Action of Rowachol are to inhibit hepatic 3-hydroxy-3-methylglutaric
 acid(HMG)-coenzyme A(CoA) reductase, to inhibits cholesterol nucleation in bile from patients
 with cholesterol gallstones, and to promote biliary lipid secretion.

 The purpose of this study is to determine whether Rowachol is useful in the prevention of PCS
 and symptoms change after laparoscopic cholecystectomy
Inclusion Criteria:

 -  Patients with pathologic diseases scheduled for laparoscopic cholecystectomy

 Exclusion Criteria:

 -  Current immunosuppressive therapy

 -  Chemotherapy within 4 weeks before operation

 -  Radiotherapy completed longer than 4 weeks before operation

 -  Inability to follow the instructions given by the investigator

 -  Severe psychiatric or neurologic diseases

 -  Drug- and/or alcohol-abuse according to local standards

 -  Participation in another intervention-trial with interference of a primary or
 secondary endpoint of this study

 -  Lack of compliance

 -  Lack of informed consent